Hungarian drugmaker Richter Gedeon says that consolidated sales for full-year 2005 grew 12.7% year-on-year to 168.34 billion forint ($806.2 million), on strong sales in the Commonwealth of Independent States.
During the period, operating profit rose 4.8% to 38.58 billion forint and operating margins were comparable to the previous year's at 22.9% versus 24.6%, while the group's diluted earnings rose 12.2% to 2,403 forint per share as net profit reached $44.71 billion forint.
EU sales decline while CIS booms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze